GCCL Launches Neutralizing Antibody Analysis Service for Vaccines and Therapeutics

[Asia Economy Reporter Lee Gwan-joo] Clinical trial specimen analysis institution GCCL announced on the 30th that it will provide neutralizing antibody analysis services for vaccines and therapeutics against infectious viral diseases.

The newly introduced services are the Plaque Reduction Neutralization Test (PRNT) and the Focus Reduction Neutralization Test (FRNT). These are the primary analytical methods required to verify the efficacy of substances during clinical trials.

Both methods are characterized by advantages such as high reproducibility and objectivity. In particular, FRNT reduces the neutralizing antibody measurement time, which typically takes about 5 to 10 days, to a short period (2 to 3 days), and allows simultaneous measurement of neutralizing antibodies in multiple samples. The company explained that after establishing this analysis service, it has completed verification using the World Health Organization (WHO) standard serum employed for validating the service.

Lee Hee-joo, Head of Research Operations at GCCL, stated, "We expect this to assist developers struggling with clinical trials due to the lack of facilities for neutralizing antibody analysis of new and variant infectious disease viruses."

This content was produced with the assistance of AI translation services.